Novartis is getting global rights to a Monte Rosa Therapeutic molecular glue degrader drug in early clinical testing as a potential treatment for autoimmune disorders. The deal comes months after the pharma giant landed rights to an Arvinas targeted protein degrader for cancer.
The post Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications appeared first on MedCity News.
